AIDX

PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood ("MCED") test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services ("NDS"). NDS will provide ultrasound services and medical oversight in

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories. Early in the COVID-19 pandemic, 20/20 Biolabs was among the first companies in the U.S. to import, validate, and dis

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

10-Q - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March

NEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference taking place Wednesday and Thursday, May 20-21, 2026. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times EDTWednesday, May 20, 2026 (Day 1)8:30-9:00Huize Holding Limited (HUIZ)*****9:15-9:45U Power Limited (UCAR)SuperCom (SPCB)10:00-10:30InTest Corporation (INTT)Dyadic Applied BioSolutions (DYAI)10:45-11:15International Battery Metals (IBATF)A2Z Cust2mate (AZ)11:30

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference. 20/20 BioLabs' Chief Executive Officer, Jonathan Cohen, will participate in one-on-one investor meetings and host a presentation from 3:15 PM ET to 3:45 PM ET in Track 1. Mr. Cohen will discuss the Company's recently reported quarterly results, recent partnership and licensing activity, and the plans to scale the OneTest platform. Sidoti Virtual Micr

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs' AI-Enabled Multi-Cancer Early Detection Platform GAITHERSBURG, Md., May 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team headed by James Hébert, Sc.D., Director of the South

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

EFFECT - 20/20 Biolabs, Inc. (0001139685) (Filer)

EFFECT - 20/20 Biolabs, Inc. (0001139685) (Filer)

Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's National Practitioner Network WASHINGTON, Conn. and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases today announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, a leading marketplace that enables functional and integrative medicine practitioners to easily d

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

S-1 - 20/20 Biolabs, Inc. (0001139685) (Filer)

POS AM - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)